Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence

Background: Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)]. Methods: We studied 163,490 unique women aged 50–79 years enrolled in Group Health (Washington State) between 1994–2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no). Results: Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (Ptrend ≤ 0.05) for all HT users, except EPT current users (Ptrend = 0.68); DCIS rates did not change in any group. Conclusions: Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression. Impact: Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency. Cancer Epidemiol Biomarkers Prev; 21(5); 720–7. ©2012 AACR.

[1]  E L Korn,et al.  Predictive Margins with Survey Data , 1999, Biometrics.

[2]  D. Miglioretti,et al.  Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. J. Brenner.  4–11 Reported Drop in Mammography: Is This Cause for Concern? , 2008 .

[4]  J. Peterse,et al.  Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations , 2008, Breast Cancer Research and Treatment.

[5]  C. Navarro,et al.  Recent Changes in Breast Cancer Incidence in Spain, 1980–2004 , 2009, Journal of the National Cancer Institute.

[6]  D. Miglioretti,et al.  Hormone Therapy Prescribing Patterns in the United States , 2004, Obstetrics and gynecology.

[7]  P. W. Lane,et al.  Analysis of covariance and standardization as instances of prediction. , 1982, Biometrics.

[8]  Emily White,et al.  Evaluating Organized Breast Cancer Screening Implementation , 2004, Cancer Epidemiology Biomarkers & Prevention.

[9]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[10]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[11]  K. Kerlikowske,et al.  Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Hyland,et al.  Table 6 , 2004 .

[13]  S. Rosso,et al.  Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.

[14]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2007, Featuring Tumors of the Brain and Other Nervous System , 2011, Journal of the National Cancer Institute.

[15]  J. Dungan.  The Decrease in Breast-Cancer Incidence in 2003 in the United States , 2008 .

[16]  B. Anderson.  Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. , 2007, Journal of the National Cancer Institute.

[17]  Robert N Hoover,et al.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.

[18]  Jasmin A. Tiro,et al.  Reported drop in mammography , 2007, Cancer.

[19]  T. Onega,et al.  Screening mammography intervals among postmenopausal hormone therapy users and nonusers , 2009, Cancer Causes & Control.

[20]  Eric J Feuer,et al.  The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.

[21]  D. Miglioretti,et al.  Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. , 2007, Journal of the National Cancer Institute.

[22]  Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial , 2011 .

[23]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[24]  R. Rawal,et al.  Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy , 2008, Breast Cancer Research and Treatment.

[25]  G. Elfenbein.  A decline in breast-cancer incidence. , 2007, The New England journal of medicine.

[26]  S. Heckbert,et al.  A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. , 2004, American journal of epidemiology.

[27]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[28]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[29]  Sarah M. Greene,et al.  Retention of enrollees following a cancer diagnosis within health maintenance organizations in the Cancer Research Network. , 2004, Journal of the National Cancer Institute.